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OBJECTIVES: Health care decision-making processes,
including public reimbursement of pharmaceuticals, fall
under the responsibility of individual European states,
with each country developing its own pharmacoeconomic
evaluation recommendations. Each guideline addresses
HRQL and utility assessment issues but vary in content
and approach. The objective of this study was to provide
an understanding of these differences. METHODS:
MEDLINE and government agency searches were per-
formed to identify pharmacoeconomic guidelines pub-
lished in Europe. Recommendations on HRQL and utility
evaluation were extracted and compared across guide-
lines. RESULTS: Guidelines on conducting health eco-
nomic evaluation studies were found in 14 European
countries. Ten were directly or closely related to the reim-
bursement authorities, while 4 had academic origin. Four
different recommendations were proposed for evaluating
HRQL outcomes: 1) Disease-speciﬁc and generic instru-
ments should be used together (France, The Netherlands,
Poland, Portugal); 2) Either speciﬁc and/or generic instru-
ments should be used depending on the objectives of 
the health economic study (Belgium, Hungary); 3) Only
generic HRQL measures should be used only (Denmark,
Spain); and 4) Three types of HRQL instruments should
be used simultaneously in health economic evaluations:
generic, disease-speciﬁc and utility-based HRQL instru-
ments (Italy). Four countries did not recommend pre-
ferred methods for HRQL evaluation in their guidelines
(Germany, Finland, Norway, UK). With respect to utility
assessment, there appeared to be some consensus across
guidelines: the EQ-5D and the HUI are acceptable instru-
ments for estimating utilities indirectly, while the time-
trade-off and the standard gamble methods are the most
accepted methods for the direct measurement of utilities.
CONCLUSIONS: Although there appears to be agree-
ment on the preferred choice of utility-based instruments,
recommendations for psychometrically-based HRQL
evaluation vary substantially across guidelines published
in various European countries.
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OBJECTIVES: To measure average levels of population
health for 191 WHO Member States in the year 2000 and
for each subsequent year. WHO has recognized the fun-
damental need for cross-population comparable data on
health and various other categories of evidence for health
policy. This paper outlines the conceptual basis for the
description and measurement of health embodied in
recent WHO work. METHODS: WHO has developed
new methods to improve the comparability of self-report
data across countries, and used these in the WHO Multi-
country Household Survey Study to obtain comparable
measures of health state prevalences for 58 countries. For
measurement purposes, health is operationalized in terms
of levels on a core set of health domains, each character-
ized by a single cardinal scale of capacity. Healthy life
expectancy (HALE) estimates are based on analysis of
mortality for 191 countries, disability for 130 causes for
17 regions of the world, and an analysis of 63 health
surveys in 55 countries. RESULTS: HALE at birth ranges
from a low of 39 years for African women to a high of
72 years in developed countries. The equivalent “lost”
healthy years range from 20% of total life expectancy at
birth in Africa to 11–12% in the European and Western
Paciﬁc regions. The sex gap is highest for Eastern Europe
and lowest in North Africa and the Middle East. 
CONCLUSIONS: The new methods used in the WHO
Multi-country Household Survey Study have increased
the comparability of self-report data across countries, a
major step forward in the use of self-reported data on
health. Health is conceptualized as a set of health domain
capacities, rather than of quality of life, well-being or
utility. Building on this experience, WHO is developing
improved health status measurement techniques for a
World Health Survey to be carried out in 2002.
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OBJECTIVE: The objective of this study was to assess
patient-derived utility estimates for clinical and histolog-
ical health states representing variation in chronic hepati-
tis C (CHC) associated disease severity. METHODS: A
total of 428 patients with CHC participated in a cross-
sectional interview-based study using the utility measure-
ment methods rating scale (RS) and EuroQoL (EQ-5D).
Current clinical and histological health status was
